about
Ability of HIV-1 Nef to downregulate CD4 and HLA class I differs among viral subtypesStructure of TCR and antigen complexes at an immunodominant CTL epitope in HIV-1 infectionCharacteristics and outcomes of initial virologic suppressors during analytic treatment interruption in a therapeutic HIV-1 gag vaccine trialEfficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cellsAntigen load and viral sequence diversification determine the functional profile of HIV-1-specific CD8+ T cellsThe major genetic determinants of HIV-1 control affect HLA class I peptide presentation.Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection.Evidence of differential HLA class I-mediated viral evolution in functional and accessory/regulatory genes of HIV-1Phylogenetic dependency networks: inferring patterns of CTL escape and codon covariation in HIV-1 Gag.HLA-associated immune escape pathways in HIV-1 subtype B Gag, Pol and Nef proteins.Quantitative trait loci for CD4:CD8 lymphocyte ratio are associated with risk of type 1 diabetes and HIV-1 immune control.Viral adaptation to immune selection pressure by HLA class I-restricted CTL responses targeting epitopes in HIV frameshift sequences.Competitive fitness assays indicate that the E138A substitution in HIV-1 reverse transcriptase decreases in vitro susceptibility to emtricitabineLimited evolution of inferred HIV-1 tropism while viremia is undetectable during standard HAART therapyImpaired replication capacity of acute/early viruses in persons who become HIV controllers.Prevalence and virologic consequences of transmitted HIV-1 drug resistance in UgandaGag-protease-mediated replication capacity in HIV-1 subtype C chronic infection: associations with HLA type and clinical parametersEarly selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infectionPredictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy.Technical and regulatory shortcomings of the TaqMan version 1 HIV viral load assayAdaptation of HIV-1 to human leukocyte antigen class ITrends in plasma HIV-RNA suppression and antiretroviral resistance in British Columbia, 1997-2010Factors associated with viral rebound in HIV-1-infected individuals enrolled in a therapeutic HIV-1 gag vaccine trial.Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C.The impact of clinical, demographic and risk factors on rates of HIV transmission: a population-based phylogenetic analysis in British Columbia, Canada.Genotypic and functional impact of HIV-1 adaptation to its host population during the North American epidemic.Definition of the viral targets of protective HIV-1-specific T cell responsesUncommon pathways of immune escape attenuate HIV-1 integrase replication capacity.HIV drug resistance testing by high-multiplex "wide" sequencing on the MiSeq instrument.Estimating the Respective Contributions of Human and Viral Genetic Variation to HIV ControlLack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals.Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1.HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy.The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes.Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes.Marked epitope- and allele-specific differences in rates of mutation in human immunodeficiency type 1 (HIV-1) Gag, Pol, and Nef cytotoxic T-lymphocyte epitopes in acute/early HIV-1 infectionHLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1.Replication fitness of multiple nonnucleoside reverse transcriptase-resistant HIV-1 variants in the presence of etravirine measured by 454 deep sequencingHLA-associated viral mutations are common in human immunodeficiency virus type 1 elite controllers.Transmission and long-term stability of compensated CD8 escape mutations.
P50
Q21245213-4FBE5FBA-9395-4F27-A8A0-892EFB8275C7Q27680531-E25905B0-FAFC-4E8F-84D7-A1EBAAE5996AQ28730828-A303582B-19C3-4725-AACE-504CC0372CF9Q28748976-513A760D-113E-4F81-8C96-918684824672Q28754733-A01464D8-9C62-498E-9FAF-72FD91C97477Q29417018-15ACC702-9358-4DE1-8CA6-D136A494F7FAQ30469621-66E6C29C-EED1-4AEC-9D74-BC648621EBA8Q33290217-E0BF085F-1500-4864-82BE-D3DD5916EC4FQ33385995-1D77EA72-5CB0-4982-A0CA-203F5FE057BBQ33494829-862644D9-D33A-4494-A3F4-C123CD4D863BQ33571769-BB6BDC0F-7F5D-4815-A8B6-AE59637AFA1BQ33615145-3E860151-2D1D-4E78-A2C8-E20A734FC983Q33623030-3806774A-57F9-4F02-A0AC-530E2AA20046Q33721466-3E3283E8-3F94-474E-A34F-025E86F40057Q33963989-5D871554-D299-4614-9E9D-7458AA2654BEQ34116836-C27BDA45-139E-4D4E-BDE7-22DFAEA4329BQ34178349-9D22951D-1BAF-485F-B4F6-119295224068Q34295972-95A2EC42-7AC7-4CF2-B680-918C673F28E5Q34381830-D6BAC1FB-6F05-4EC3-B142-4308D49CBAEBQ34399511-B8018D7D-0A34-40F8-BA32-9440041B8318Q34604811-23AE1A43-4DFE-458E-8FF9-0AEFB6C7AC06Q34702301-4CD6BC1B-2055-49EC-9EFE-342948524632Q34743309-DCB4989B-F83A-4A8B-B29E-585C790D211BQ35076519-D9EED179-F0AB-48E0-B1B7-BEB715E5CD84Q35152768-28C64EBA-9E3D-4114-80CC-AB02F58C2D96Q35156765-29BEC0C0-F092-451E-854A-0BA2402E3E6FQ35800157-0CA97AF3-0F96-48AE-A0C4-6BDB0102B2B5Q36086711-50AA764F-BB3F-49D9-BD29-AD287C7B92F6Q36158371-7D3D9BCB-7FDD-4517-ACF5-8D09A1BA3DABQ36275248-C7D7A531-06D5-4D98-A55B-E56177F63D8CQ36301732-AE892123-5778-4029-9842-297A831CB4C9Q36414604-1420D092-D6A4-4BE3-95FE-0D3310656D01Q36711015-6D7F0065-6493-4DC0-B17C-6906560E361BQ36712414-739E77F0-5B36-4048-9BA2-06F0BDD803CFQ36845893-24008F20-930A-45E2-AAD9-FCC14CADC25DQ36898637-0A94637B-0359-4C82-9242-D24308C9DCFEQ37033250-EAC544AC-EF24-4F5C-95B4-CAACB85A5D8AQ37036804-E8B3374B-276A-4036-879A-B7B7ADD0EC3DQ37127920-B21D35A4-F3EA-4380-97B4-342F679A3239Q37145270-7DC1AB8D-109B-417B-9D6C-1A8F391E3838
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Chanson Brumme
@fr
Chanson J Brumme
@en
Chanson J Brumme
@es
Chanson J Brumme
@nl
Chanson J Brumme
@sl
type
label
Chanson Brumme
@fr
Chanson J Brumme
@en
Chanson J Brumme
@es
Chanson J Brumme
@nl
Chanson J Brumme
@sl
prefLabel
Chanson Brumme
@fr
Chanson J Brumme
@en
Chanson J Brumme
@es
Chanson J Brumme
@nl
Chanson J Brumme
@sl
P106
P31
P496
0000-0003-2722-5288